Figure 3
![Figure 3. Age effect on outcome. CALGB patients aged 16 to 17 years had a 7-year EFS of 55%, which was similar to a 64% EFS for 16- to 17-year-old CCG patients (P = .49). CALGB patients aged 18 to 20 years old had a 7-year EFS of 29%, which was significantly worse than that for the younger CALGB patients and the 57% EFS for 18- to 20-year-olds on CCG trials (P = .01; RHR, 2.1 [CI, 1.2-3.8]).](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/112/5/10.1182_blood-2008-01-130237/5/zh80160821890003.jpeg?Expires=1735834043&Signature=0-jOngDvm2LuoX~3n7IbH259v-hzfdA93hSj0O8UlXuZ2uuBFTRfJ6QskiEAC3jXAQYh65gTAncifcZQsCUfymlt~gk0QOMke5o33XQG2lIskl9lRFAsCSMiJJwijTfJZk7lxQuoiSKLZSaxArB~UtNMd~X8RpOg08kacfwvdKUsw1IBZGjNjetyJASgzZt0dIQkw2ZshWclwZ6mk8X~V8EeFCab8wpr9PnaJtXPOXi4pdzyHelAc6bp~raLgpDii3n0gm453~ZVQ2J6YtkX0JcJ~ZzEK~rcRgtxdkWhcbN8oE8Cg7rtFS-j4TBrkRY880Vpo6fsuKUSDUCKaiHpVA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Age effect on outcome. CALGB patients aged 16 to 17 years had a 7-year EFS of 55%, which was similar to a 64% EFS for 16- to 17-year-old CCG patients (P = .49). CALGB patients aged 18 to 20 years old had a 7-year EFS of 29%, which was significantly worse than that for the younger CALGB patients and the 57% EFS for 18- to 20-year-olds on CCG trials (P = .01; RHR, 2.1 [CI, 1.2-3.8]).
